Eric W. Roberts Purchases 53,333 Shares of CalciMedica, Inc. (NASDAQ:CALC) Stock

CalciMedica, Inc. (NASDAQ:CALC) insider Eric W. Roberts bought 53,333 shares of the company’s stock in a transaction on Friday, November 1st. The shares were bought at an average price of $3.75 per share, for a total transaction of $199,998.75. Following the completion of the acquisition, the insider now directly owns 164,706 shares in the company, valued at approximately $617,647.50. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

CalciMedica Stock Down 5.1 %

Shares of CALC opened at $3.51 on Friday. The stock has a market capitalization of $37.73 million, a P/E ratio of -2.51 and a beta of 1.30. CalciMedica, Inc. has a twelve month low of $2.14 and a twelve month high of $8.38. The company has a 50 day moving average of $4.25 and a 200-day moving average of $4.63.

CalciMedica (NASDAQ:CALC) last released its earnings results on Monday, August 12th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.03. On average, sell-side analysts anticipate that CalciMedica, Inc. will post -2.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CalciMedica

An institutional investor recently raised its position in CalciMedica stock. Atria Investments Inc raised its holdings in shares of CalciMedica, Inc. (NASDAQ:CALC) by 136.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,503 shares of the company’s stock after purchasing an additional 15,296 shares during the quarter. Atria Investments Inc owned approximately 0.25% of CalciMedica worth $117,000 at the end of the most recent reporting period.

Analyst Ratings Changes

CALC has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of CalciMedica in a report on Tuesday, August 13th. Oppenheimer raised their price target on shares of CalciMedica from $14.00 to $20.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 10th.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.